GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

Ultragenyx Pharmaceutical received accelerated approval from the FDA for Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients 8 years and older with glycogen storage disease type Ia (GSDIa), the company announced on August 19, 2026.¹ The approval marks the company's fifth FDA approval and its first for a gene therapy product.

GSDIa is an ultra-rare, inherited metabolic disorder caused by pathogenic variants in the gene encoding glucose-6-phosphatase, an enzyme needed to release glucose from the liver into the bloodstream.¹ Without it, patients face a constant risk of severe, potentially life-threatening low blood sugar and must follow an around-the-clock regimen of raw cornstarch intake to maintain stable glucose levels. The condition affects an estimated 1500 to 2500 patients in the United States and 6000 to 8000 worldwide in commercially accessible regions.

What Did the Clinical Trial Show?

The approval rests on data from the phase 3 GlucoGene study, a 48-week randomized, double-blind, placebo-controlled trial that enrolled 46 participants.¹ Those who received the therapy showed a statistically significant reduction in daily cornstarch requirements compared with placebo. Following the initial 48-week period, eligible participants crossed over to receive the alternate treatment, with follow-up analyses planned at 96 and 144 weeks to track longer-term outcomes.

“Day-to-day management of GSDIa requires a relentless regimen of raw cornstarch and strict dietary management that can be extraordinarily demanding for patients and families. Even with meticulous adherence to this regimen, patients must be perfect. Any missed cornstarch puts patients at risk of severe hypoglycemia, seizures, and even death,” said David Weinstein, MD, MMSc, a longtime researcher in the GSDIa field, in a press release.¹ “The approval of Genglycos represents a major step forward for the GSDIa community and reflects almost 30 years of work and scientific progress aimed at improving safety and the quality of life of people living with this disease.”

How Does This Approval Affect Pharma Development and Manufacturing Broadly?

Since the therapy was cleared under the accelerated approval pathway, continued marketing authorization depends on confirmatory evidence of clinical benefit.¹ Ultragenyx has committed to a post-marketing disease monitoring program that will follow 50 treated patients and 20 untreated control patients, the latter excluded from treatment due to preexisting antibodies to the viral vector, over a projected 10-year period. That structure illustrates how sponsors of ultra-rare disease gene therapies are increasingly relying on long-term, real-world monitoring to satisfy regulators when trial populations are too small to generate conventional statistical power.

The therapy also carries a boxed set of warnings common to adeno-associated virus vector gene therapies, including hypersensitivity reactions, immune-mediated liver toxicity, and adrenal insufficiency tied to the corticosteroid regimen used to manage hepatic reactions.¹ Distribution will run through a national network of qualified treatment centers trained to administer the therapy, an access model increasingly used for specialized cell and gene therapy products that require infusion oversight and long-term patient monitoring beyond what a typical infusion center provides.

“As our first gene therapy approval, Genglycos represents an important achievement for our company and the realization of the promise of a powerful new tool to deliver transformative medicines for people living with rare diseases,” said Eric Crombez, MD, chief medical officer, Ultragenyx, in the press release.¹

The product is manufactured entirely at Ultragenyx's gene therapy manufacturing facility in Bedford, Massachusetts, a detail relevant to ongoing conversations in the sector about internalizing viral vector production rather than depending on external capacity.¹ As more gene therapy sponsors weigh build-versus-buy manufacturing decisions, cases like this one offer a data point on how in-house facilities can support both scale-up and consistent quality control for accelerated-approval products.

Why Do Therapy Sponsors Build Their Own Manufacturing Capacity Instead of Outsourcing?

Ultragenyx's decision to manufacture Genglycos entirely in-house reflects a build-versus-buy calculation that has become increasingly common across the gene therapy sector.² Viral vector production, particularly for AAV-based therapies used in vivo, requires specialized biosafety containment, nucleic acid workflows, and scale-up expertise that many contract development and manufacturing organizations (CDMOs) still struggle to deliver quickly. Industry reporting has noted that CDMO wait times for viral vector production slots can exceed 18 months, a delay that larger, well-resourced sponsors often choose to avoid by internalizing production. Building in-house capacity also allows a company to retain control over its manufacturing process and intellectual property, an advantage particularly relevant for orphan drug programs where development timelines are already compressed. For sponsors without the capital or technical experience to construct a dedicated facility, however, outsourcing, despite its scheduling constraints, often remains the only practical path to commercial supply.

Reference

1. Ultragenyx announces U.S. FDA approval of GENGLYCOS™ gene therapy, the first-ever FDA-approved treatment designed to treat the underlying cause of glycogen storage disease type Ia (GSDIa). Press Release. Ultragenyx Pharmaceutical Inc. August 19, 2026. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-us-fda-approval-genglycostm-gene-therapy
2. Strategies for viral vector manufacturing. Press Release. Cytiva. February 16, 2025. https://www.cytivalifesciences.com/en/us/insights/strategies-for-viral-vector-manufacturing